NCT03595917 2025-11-04ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLDana-Farber Cancer InstitutePhase 1 Recruiting40 enrolled
NCT04838041 2025-07-30Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationMedical College of WisconsinPhase 2 Recruiting51 enrolled
NCT04835584 2022-03-21KRT-232 and TKI Study in Chronic Myeloid LeukemiaKartos Therapeutics, Inc.Phase 1/2 Recruiting109 enrolled